AMLX / Could Amylyx Pharmaceuticals Have a Blockbuster ALS Treatment?

Amylyx Pharmaceuticals shares fell Friday after its ALS (amyotrophic lateral sclerosis) drug was denied marketing authorization by European Union regu more_horizontal

Amylyx Pharmaceuticals Inc. AMLX, -4.60% shares fell 7.5% premarket on Friday after the company said the European Medicines Agency had confirmed its n more_horizontal

Amylyx Pharmaceuticals said on Friday the European Union medicines regulator for the second time declined to recommend a marketing authorisation for t more_horizontal

Amylyx Pharmaceuticals, Inc. (AMLX) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.01 per share. This more_horizontal

Clinical trials can be like a tightrope over a minefield for biotech investors. Only a fraction of drugs even succeed through clinical trials to recei more_horizontal

Amylyx focuses on neurodegenerative diseases. After launching its first product in September, the company turned its first profitable quarter. more_horizontal

Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of more_horizontal

Amylyx Pharmaceuticals and Viking Therapeutics have been on fire over the past year. Even so, both companies still look incredibly undervalued relativ more_horizontal